RT Journal Article
SR Electronic
T1 New and future therapies for lupus nephritis
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 134
OP 140
DO 10.3949/ccjm.78gr.11004
VO 79
IS 2
A1 Gerald B. Appel
YR 2012
UL http://www.ccjm.org/content/79/2/134.abstract
AB Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.